Abstract 15744: Factor XIa Inhibition for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis of Randomized Control Trials
Faktor-XIa-Hemmung zur sekundären Schlaganfallprävention: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.15744 ↗Auf einen Blick
Sechs Studien mit 16.501 Patient:innen zeigen: Faktor-XIa-Inhibition senkte rezidivierende ischämische Schlaganfälle und vaskuläre Ereignisse, ohne die Blutungs-, ICB- oder Mortalitätsrate signifikant zu erhöhen.
Fragestellung
Reduziert eine Faktor-XIa-Hemmung bei Patient:innen nach ischämischem Schlaganfall oder Hochrisiko-TIA rezidivierende Schlaganfälle und vaskuläre Ereignisse ohne mehr schwere Blutungen?
Methode
Systematische Suche in PubMed, Embase und Cochrane Library Central bis April 2026; Vergleich FXIa mit Placebo; Metaanalyse mit random-effects-Modell.
Ergebnisse
Rekurrenter IS: 5,8 % vs. 8,0 %; RR 0,76 (95 %-KI 0,68–0,86). Major vascular composite: 8,8 % vs. 10,9 %; RR 0,84 (95 %-KI 0,76–0,93). Keine signifikanten Unterschiede bei major bleeding, ICB oder Mortalität.
Einschränkungen
Die Hauptaussage stützt sich laut Autoren vor allem auf eine Studie; Unterschiede bei Wirkstoff, Dosis, Follow-up und Blutungsdefinitionen.
Schlussfolgerung der Autor:innen
FXIa-Hemmung war mit weniger rezidivierenden Schlaganfällen und vaskulären Ereignissen assoziiert, ohne signifikanten Anstieg von Blutungen, ICB oder Mortalität. Die Autoren sehen darin einen vielversprechenden Ansatz zur sekundären Schlaganfallprävention.
Kernaussagen
- Rekurrenter IS: RR 0,76 (95 %-KI 0,68–0,86)
- Major vascular composite: RR 0,84 (95 %-KI 0,76–0,93)
- Keine signifikanten Unterschiede bei Blutung, ICB oder Mortalität
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Omar kasimieh und 6 weiteren Autor:innen.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
There is a high risk of recurrent ischemic stroke (IS) or transient ischemic attack (TIA) for patients with a recent history of IS or high-risk TIA. FXIa inhibition is a novel antithrombotic agent with the potential to reduce thrombosis while preserving hemostasis. However, the clinical evidence from randomized controlled trials of FXIa inhibitors has yet to be pooled systematically. Research Question: The primary objective was to evaluate whether FXIa inhibition reduces recurrent ischemic stroke and vascular events without increasing major bleeding, intracranial hemorrhage, or mortality compared with placebo in patients with recent ischemic stroke or high-risk TIA.
Methods
We systematically searched PubMed, Embase, and Cochrane Library Central through April 2026 for studies comparing FXIa with placebo for secondary prevention of IS and TIA. Risk ratios with 95% confidence intervals were calculated for each study and pooled using the Mantel-Haenszel method in a random-effects model with R. The degree of heterogeneity in the studies was evaluated with the I 2 statistic.
Results
Six studies including 16,501 patients were analyzed, with 9,189 patients (55.7%) assigned to FXIa inhibitors, including 7,514 receiving asundexian and 1,675 receiving milvexianFXIa inhibition was associated with a significant reduction in the number of patients with recurrent IS (5.8% vs 8.0%; RR 0.76, 95% CI 0.68-0.86, p < 0.0001, I 2 = 0%) and the major vascular composite outcome (8.8% vs 10.9%; RR 0.84, 95% CI 0.76-0.93, p = 0.0006, I 2 = 0%). There was no significant difference in the number of patients with major bleeding (RR 1.13, 95% CI 0.89-1.45, p = 0.32, I 2 =0%), major or clinically relevant nonmajor bleeding (RR 1.16, 95% CI 0.91-1.48, p = 0.24, I 2 =17.8%), symptomatic intracranial hemorrhage (RR 1.11, 95% CI 0.73-1.70, p = 0.62, I 2 =0%), or all-cause mortality (RR 1.00, 95% CI 0.85-1.18, p = 0.97, I 2 =0%)
Conclusions
FXIa inhibition is associated with a significant reduction in the number of patients with recurrent IS or vascular events after an initial diagnosis of IS or high-risk TIA, but not with a significant increase in major bleeding, intracranial hemorrhage, or mortality. Therefore, FXIa inhibition may present a promising new agent for the secondary prevention of stroke. However, the main evidence supporting this conclusion comes from only one trial, thereby limiting its strength. Additionally, differences in agents, doses, follow-up periods, and definitions of bleeding events across trials should be considered when interpreting these results.
Zitieren
APA
kasimieh, O., Diaz-Gutierrez, M., Sued, E., Quiros, M., Machado, G. F., Naveed, H., & Sarswat, N. (2026). Abstract 15744: Factor XIa Inhibition for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis of Randomized Control Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.15744
Vancouver
kasimieh O, Diaz-Gutierrez M, Sued E, Quiros M, Machado GF, Naveed H, et al. Abstract 15744: Factor XIa Inhibition for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis of Randomized Control Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.15744
BibTeX
@article{kasimieh2026,
author = {kasimieh, Omar and Diaz-Gutierrez, Maria and Sued, Evelyn and Quiros, Marco and Machado, Guilherme Franceschini and Naveed, Hamza and Sarswat, Nitasha},
title = {Abstract 15744: Factor XIa Inhibition for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis of Randomized Control Trials},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.15744}
}
EUVIMED